. 2021 Apr 15;11:8288. doi: 10.1038/s41598-021-87417-2

Table 3.

Potency (pEC₅₀) and maximal effect (E_max) estimates for agonists activating D₂R G protein signalling pathways.

Agonist	Gα_i1		Gα_oA		GIRK
Agonist	pEC₅₀	E_max	pEC₅₀	E_max	pEC₅₀	E_max
Dopamine	7.50 ± 0.09	100.0	8.63 ± 0.08	100.0	8.70 ± 0.06	100.0
Apomorphine	8.10 ± 0.07	103.6 ± 2.5	9.07 ± 0.06	98.6 ± 1.9	9.13 ± 0.08	110.0 ± 3.5
Aripiprazole	6.21 ± 0.17	67.5 ± 6.9	6.64 ± 0.08	97.6 ± 3.8	ND	ND
Bromocriptine	7.07 ± 0.08	115.0 ± 4.1	7.84 ± 0.05	103.7 ± 2.0	7.38 ± 0.08	104.7 ± 4.3
Cabergoline	8.13 ± 0.16	109.8 ± 6.5	8.80 ± 0.05	102.7 ± 1.7	9.01 ± 0.08	104.0 ± 3.4
MLS1547	5.71 ± 0.20	123.9 ± 19.5	6.68 ± 0.08	106.5 ± 4.4	ND	ND
Pergolide	7.73 ± 0.17	112.3 ± 7.3	8.73 ± 0.07	96.7 ± 2.3	9.28 ± 0.07	97.9 ± 2.7
Quinpirole	7.81 ± 0.10	119.3 ± 4.6	8.93 ± 0.05	97.4 ± 1.5	8.98 ± 0.05	104.9 ± 2.1
Ropinirole	7.33 ± 0.13	98.01 ± 5.2	8.55 ± 0.13	93.9 ± 3.7	8.23 ± 0.07	94.4 ± 3.4
Roxindole	8.19 ± 0.12	86.6 ± 4.2	9.04 ± 0.04	90.7 ± 1.1	9.26 ± 0.06	89.7 ± 2.2
Terguride	7.76 ± 0.18	66.2 ± 4.6	8.36 ± 0.05	100.1 ± 1.6	8.05 ± 0.08	53.3 ± 2.1
UNC9994	5.74 ± 0.21	81.6 ± 13.4	6.55 ± 0.08	98.0 ± 4.1	ND	ND

Concentration–response curves from Fig. 5 were analyzed using a three-parameter fit (Eq. 1). Values represent the mean ± SEM. ND Not determined: unable to be determined due to insufficient response to allow accurate fitting of the model.